Therapeutic Targetability Rankings

📖 Wiki Page

mechanism1109 wordssynced 2026-04-02

Therapeutic Targetability Rankings

Overview

flowchart TD Therapeutic_Targetability_Rank["Therapeutic Targetability Rankings"] Therapeutic_Targetability_Rank["page"] Therapeutic_Targetability_Rank -->|"related to"| Therapeutic_Targetability_Rank style Therapeutic_Targetability_Rank fill:#81c784,stroke:#333,color:#000 Therapeutic_Targetability_Rank["ranks"] Therapeutic_Targetability_Rank -->|"related to"| Therapeutic_Targetability_Rank style Therapeutic_Targetability_Rank fill:#81c784,stroke:#333,color:#000 Therapeutic_Targetability_Rank["neurodegenerative"] Therapeutic_Targetability_Rank -->|"related to"| Therapeutic_Targetability_Rank style Therapeutic_Targetability_Rank fill:#81c784,stroke:#333,color:#000 style Therapeutic_Targetability_Rank fill:#4fc3f7,stroke:#333,color:#000

This page ranks neurodegenerative disease mechanisms by their tractability for therapeutic intervention, considering factors including genetic validation, drug discovery history, and clinical feasibility. Targetability rankings help prioritize research investment and identify promising therapeutic approaches. [@drug2024]

Targetability depends on multiple factors: druggability of the target, availability of relevant biomarkers, clinical trial design feasibility, and safety considerations. [@als2023]

--- [@drug2023]

AD Targetability Rankings

Tier 1: Highly Targetable

...

Therapeutic Targetability Rankings

Overview

Mermaid diagram (expand to render)

Targetability depends on multiple factors: druggability of the target, availability of relevant biomarkers, clinical trial design feasibility, and safety considerations. [@als2023]

--- [@drug2023]

AD Targetability Rankings

Tier 1: Highly Targetable

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage | [@target2022]
|------|--------|-----------|---------------------|----------------|
| 1 | [BACE1](/entities/bace1) | Amyloid production | Small molecule | Failed |
| 2 | AChE | Neurotransmission | Small molecule (approved) | Approved |
| 3 | [NMDA receptor](/entities/nmda-receptor) | Excitotoxicity | Small molecule (approved) | Approved |
| 4 | [Amyloid-beta](/proteins/amyloid-beta) | Aggregation | Immunotherapy | Phase III |
| 5 | [TREM2](/proteins/trem2) | [Microglia](/cell-types/microglia-neuroinflammation) | Antibody | Phase II |

Tier 2: Moderately Targetable

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 6 | [Tau](/proteins/tau) | Aggregation | Small molecule | Phase II |
| 7 | Tau | Phosphorylation | Kinase inhibitors | Research |
| 8 | Tau | Immunotherapy | Antibody | Phase II |
| 9 | HTR receptors | Neurotransmission | Small molecule | Phase II |
| 10 | PPAR | Metabolism | Small molecule | Phase II |

Tier 3: Emerging Targetability

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 11 | [Autophagy](/entities/autophagy) | Clearance | Small molecule | Preclinical |
| 12 | [NLRP3](/entities/nlrp3-inflammasome) | Inflammation | Small molecule | Phase I |
| 13 | [APOE](/proteins/apoe) | Clearance | Gene therapy | Preclinical |
| 14 | Synaptic plasticity | Function | Various | Research |
| 15 | Neurogenesis | Regeneration | Various | Research |

PD Targetability Rankings

Tier 1: Highly Targetable

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 1 | DRD2 | Dopamine receptor | Agonist (approved) | Approved |
| 2 | MAO-B | Dopamine metabolism | Inhibitor (approved) | Approved |
| 3 | COMT | Dopamine metabolism | Inhibitor (approved) | Approved |
| 4 | ADORA2A | Adenosine receptor | Antagonist | Phase III |
| 5 | [Alpha-synuclein](/proteins/alpha-synuclein) | Aggregation | Immunotherapy | Phase II |

Tier 2: Moderately Targetable

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 6 | LRRK2 | Kinase | Small molecule | Phase II |
| 7 | GBA | Enzyme | Small molecule | Phase II |
| 8 | Glutamate receptors | Excitotoxicity | Modulators | Phase II |
| 9 | neurotrophic factors | Neuroprotection | Gene therapy | Phase I/II |
| 10 | Alpha-synuclein | ASO | Antisense | Preclinical |

Tier 3: Emerging Targetability

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 11 | PINK1/PARKIN | Mitophagy | Gene therapy | Preclinical |
| 12 | Alpha-synuclein | Gene editing | CRISPR | Preclinical |
| 13 | Glial modulation | Support | Various | Research |
| 14 | Iron chelation | Oxidative stress | Small molecule | Phase II |
| 15 | Circadian targets | Rhythm | Various | Research |

ALS Targetability Rankings

Tier 1: Highly Targetable

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 1 | SOD1 | Genetic | ASO (approved) | Approved |
| 2 | Glutamate signaling | Excitotoxicity | Riluzole (approved) | Approved |
| 3 | [C9orf72](/entities/c9orf72) | Genetic | ASO | Phase I/II |
| 4 | Neurotrophin support | Protection | Various | Phase II |
| 5 | Metabolic support | Energy | Various | Phase II |

Tier 2: Moderately Targetable

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 6 | FUS | RNA processing | ASO | Preclinical |
| 7 | [TDP-43](/mechanisms/tdp-43-proteinopathy) | Splicing | ASO | Preclinical |
| 8 | ATXN2 | RNA processing | ASO | Preclinical |
| 9 | Inflammation | Microglia | Small molecule | Phase II |
| 10 | Cytoskeleton | Transport | Small molecule | Research |

Tier 3: Emerging Targetability

| Rank | Target | Mechanism | Drug Types Available | Clinical Stage |
|------|--------|-----------|---------------------|----------------|
| 11 | Senolytics | Cell death | Various | Preclinical |
| 12 | RNA binding proteins | Splicing | Small molecule | Research |
| 13 | Epigenetic modifiers | Transcription | Various | Research |
| 14 | Muscle targets | NMJ | Various | Research |
| 15 | Regeneration | Stem cells | Cell therapy | Research |

Targetability Assessment Criteria

Genetic Evidence

GWAS hit strength
Mendelian mutation validation
Effect size and direction
Biological plausibility

Druggability

Presence of druggable binding sites
Protein family tractability
Tissue delivery feasibility

Clinical Feasibility

Biomarker availability
Patient population size
Trial endpoint validation
Safety margin

Commercial Considerations

Market size
Competition landscape
Regulatory pathways

Emerging Target Categories

RNA-Targeted Therapies

Antisense oligonucleotides (ASOs)
RNA interference (RNAi)
Small interfering RNA (siRNA)

Gene Therapy

AAV vectors
CRISPR gene editing
Base editing

Cell Therapy

Stem cell replacement
Gene-corrected cells
Immunomodulation

Coverage Gaps

Underrepresented Target Categories

The following therapeutic target areas need more detailed mechanism pages:

Microglial modulation targets — TREM2 is covered but other microglia targets (CD33, PYROXIN, CCL2) are missing

Autophagy enhancers — Listed as Tier 3 but needs dedicated page expansion

Senolytics — Emerging area for ALS/PD, needs mechanism page

Iron homeostasis — Listed for PD but mechanism page is thin

Missing Cross-Links to Mechanism Pages

Targets that should link to detailed mechanism pages:

LRRK2 — Should link to [mechanisms/lrrk2-pathogenesis](/mechanisms/lrrk2-pathogenesis) (currently missing)

GBA/GCase — Should link to [mechanisms/gba-lysosomal-function](/mechanisms/gba-lysosomal-function) (needs creation)

PINK1/PARKIN — Should link to [mechanisms/mitophagy-pd](/mechanisms/mitophagy-pd) (needs expansion)

NLRP3 — Should link to [mechanisms/nlrp3-neuroinflammation](/mechanisms/nlrp3-neuroinflammation) (needs creation)

Recommendations

Create missing mechanism pages for Tier 2/3 targets to improve therapeutic pipeline visualization
Add clinical trial status tables for each target category
Cross-link drug candidates in development to mechanism pages

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Drug Development Pipeline Analysis (2024) (2024)](https://doi.org/10.1002/alz.13847)

[Unknown, ALS Therapeutic Development (2023) (2023)](https://doi.org/10.1038/s41582-023-00798-0)

[Unknown, PD Drug Development (2023) (2023)](https://doi.org/10.1016/j.tips.2023.01.005)

[Unknown, Target Prioritization Methods (2022) (2022)](https://doi.org/10.1038/s41592-022-01456-5)

📖 View canonical wiki page →

Therapeutic Targetability Rankings

Therapeutic Targetability Rankings

Overview

AD Targetability Rankings

Tier 1: Highly Targetable

Therapeutic Targetability Rankings

Overview

AD Targetability Rankings

Tier 1: Highly Targetable

Tier 2: Moderately Targetable

Tier 3: Emerging Targetability

PD Targetability Rankings

Tier 1: Highly Targetable

Tier 2: Moderately Targetable

Tier 3: Emerging Targetability

ALS Targetability Rankings

Tier 1: Highly Targetable

Tier 2: Moderately Targetable

Tier 3: Emerging Targetability

Targetability Assessment Criteria

Genetic Evidence

Druggability

Clinical Feasibility

Commercial Considerations

Emerging Target Categories

RNA-Targeted Therapies

Gene Therapy

Cell Therapy

Coverage Gaps

Underrepresented Target Categories

Missing Cross-Links to Mechanism Pages

Recommendations

See Also

External Links

References